SCHEMBL29506997

SCHEMBL29506997

CC(C)(C)OC(=O)N1CCN(c2cn(C(=O)OC(C)(C)C)c3ccc(Br)cc23)CC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 7/20 0.50
▸ KRAS P01116 4/20 0.45
▸ MAPT P10636 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HTR6 P50406 2/20 0.42
▸ SMARCA2 P51531 1/20 0.41
▸ SMARCA4 P51532 1/20 0.41
▸ PBRM1 Q86U86 1/20 0.41
▸ ESRRB O95718 1/20 0.41
▸ ESR1 P03372 1/20 0.41
▸ ESRRA P11474 1/20 0.41
▸ ESRRG P62508 1/20 0.41
▸ CHRM2 P08172 1/20 0.41
▸ CHRM4 P08173 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ CHRM3 P20309 1/20 0.41
▸ RBP4 P02753 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25337902 1.00 BACE1 (0.50) BACE1KRASMAPTALDH1A1LMNA
SCHEMBL25337917 0.93 BACE1 (0.48) BACE1KRASMAPTALDH1A1LMNA
SCHEMBL25428595 0.93 BACE1 (0.48) BACE1KRASMAPTALDH1A1LMNA
SCHEMBL26683845 0.91 BACE1 (0.50) BACE1KRASMAPTALDH1A1LMNA
SCHEMBL29507049 0.88 BACE1 (0.50) BACE1KRASMAPTALDH1A1LMNA
SCHEMBL25338493 0.88 BACE1 (0.50) BACE1KRASMAPTALDH1A1LMNA
SCHEMBL26683720 0.84 BACE1 (0.48) BACE1KRASMAPTALDH1A1LMNA
SCHEMBL25427941 0.84 BACE1 (0.48) BACE1KRASMAPTALDH1A1LMNA
SCHEMBL25334672 0.81 BACE1 (0.50) BACE1KRASMAPTALDH1A1LMNA
SCHEMBL26204111 0.79 HTR6 (0.45) BACE1KRASLMNAHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 — — US disclosed
EP-4221756-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca AB (SE) 2023-08-09 — — EP disclosed
CN-116249554-A Compounds and their use in the treatment of cancer 阿斯利康(瑞典)有限公司 2023-06-09 — — CN disclosed
WO-2022069520-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2022-04-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER RARA, RARG, RARB BACE1 4142/4885KRAS 101/4885MAPT 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback